Trials / Terminated
TerminatedNCT04371978
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.
Conditions
- COVID 19
- Coronavirus
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Dipeptidyl-Peptidase IV Inhibitors
- Linagliptin
- Severe Acute Respiratory Syndrome Coronavirus 2
- Sars-CoV2
- Hypoglycemic Agents
- Respiratory Tract Diseases
- Incretins
- Hormones
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linagliptin 5 MG | Linagliptin 5 mg PO once daily |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2021-04-04
- Completion
- 2021-05-04
- First posted
- 2020-05-01
- Last updated
- 2021-06-02
Locations
3 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT04371978. Inclusion in this directory is not an endorsement.